INTRODUCTION: Von Hippel-Lindau disease (VHL) is a dominantly inherited multi-system syndrome. Although pheochromocytoma is the hallmark endocrine neoplasm, pancreatic lesions occur frequently, and their management can be complex. This report describes 26 patients from a single institution with pancreatic or adrenal lesions (or both) in the background of VHL. METHODS: We reviewed records for all patients treated for adrenal (type 2 VHL) or pancreatic manifestations of VHL at our institution from 1990 to 2004. RESULTS: Forty patients with VHL were identified from 24 pedigrees; 26 (65%) had adrenal or pancreatic involvement (or both). Seven patients had isolated pheochromocytomas, 16 had isolated pancreatic lesions, and 3 had both. Of the 10 patients with pheochromocytomas, 4 had bilateral adrenal involvement. All but three pheochromocytomas were diagnosed in patients aged 40 years or younger. Of the 19 patients with pancreatic lesions, 8 had cystic lesions, 8 had neuroendocrine tumors, and 3 had both. Of 11 patients with neuroendocrine tumors, 4 had metastases (3 hepatic, 1 nodal). No patient with cystic pancreatic lesions developed carcinoma. CONCLUSIONS: VHL should be familiar to the endocrine surgeon because of the high incidence (65% in our series) of visceral endocrine lesions (pancreas 40%, adrenal gland 18%, both 7%). As seen in other hereditary endocrinopathy syndromes, pheochromocytomas are frequently bilateral; therefore,close follow-up of the contralateral gland in young patients with a unilateral lesion is critical. Cystic lesions of the pancreas may be closely monitored, whereas neuroendocrine tumors should be removed because of the risk of metastasis. Pancreatic pathology is not uncommon in VHL patients with pheochromocytoma and should be sought during the preoperative assessment.
INTRODUCTION:Von Hippel-Lindau disease (VHL) is a dominantly inherited multi-system syndrome. Although pheochromocytoma is the hallmark endocrine neoplasm, pancreatic lesions occur frequently, and their management can be complex. This report describes 26 patients from a single institution with pancreatic or adrenal lesions (or both) in the background of VHL. METHODS: We reviewed records for all patients treated for adrenal (type 2 VHL) or pancreatic manifestations of VHL at our institution from 1990 to 2004. RESULTS: Forty patients with VHL were identified from 24 pedigrees; 26 (65%) had adrenal or pancreatic involvement (or both). Seven patients had isolated pheochromocytomas, 16 had isolated pancreatic lesions, and 3 had both. Of the 10 patients with pheochromocytomas, 4 had bilateral adrenal involvement. All but three pheochromocytomas were diagnosed in patients aged 40 years or younger. Of the 19 patients with pancreatic lesions, 8 had cystic lesions, 8 had neuroendocrine tumors, and 3 had both. Of 11 patients with neuroendocrine tumors, 4 had metastases (3 hepatic, 1 nodal). No patient with cystic pancreatic lesions developed carcinoma. CONCLUSIONS:VHL should be familiar to the endocrine surgeon because of the high incidence (65% in our series) of visceral endocrine lesions (pancreas 40%, adrenal gland 18%, both 7%). As seen in other hereditary endocrinopathy syndromes, pheochromocytomas are frequently bilateral; therefore,close follow-up of the contralateral gland in young patients with a unilateral lesion is critical. Cystic lesions of the pancreas may be closely monitored, whereas neuroendocrine tumors should be removed because of the risk of metastasis. Pancreatic pathology is not uncommon in VHLpatients with pheochromocytoma and should be sought during the preoperative assessment.
Authors: P R Hammel; V Vilgrain; B Terris; A Penfornis; A Sauvanet; J M Correas; D Chauveau; A Balian; C Beigelman; D O'Toole; P Bernades; P Ruszniewski; S Richard Journal: Gastroenterology Date: 2000-10 Impact factor: 22.682
Authors: S K Libutti; P L Choyke; H R Alexander; G Glenn; D L Bartlett; B Zbar; I Lubensky; S A McKee; E R Maher; W M Linehan; M M Walther Journal: Surgery Date: 2000-12 Impact factor: 3.982
Authors: Linwah Yip; Jeffrey E Lee; Suzanne E Shapiro; Steven G Waguespack; Steven I Sherman; Ana O Hoff; Robert F Gagel; James F Arens; Douglas B Evans Journal: J Am Coll Surg Date: 2004-04 Impact factor: 6.113
Authors: S K Libutti; P L Choyke; D L Bartlett; H Vargas; M Walther; I Lubensky; G Glenn; W M Linehan; H R Alexander Journal: Surgery Date: 1998-12 Impact factor: 3.982
Authors: F Chen; T Kishida; M Yao; T Hustad; D Glavac; M Dean; J R Gnarra; M L Orcutt; F M Duh; G Glenn Journal: Hum Mutat Date: 1995 Impact factor: 4.878
Authors: P A Crossey; F M Richards; K Foster; J S Green; A Prowse; F Latif; M I Lerman; B Zbar; N A Affara; M A Ferguson-Smith Journal: Hum Mol Genet Date: 1994-08 Impact factor: 6.150
Authors: Michael Charlesworth; Caroline S Verbeke; Gavin A Falk; Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff Journal: J Gastrointest Surg Date: 2012-02-28 Impact factor: 3.452
Authors: Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens Journal: Endocr Pathol Date: 2021-01-12 Impact factor: 3.943
Authors: Marcia Helena Soares Costa; Tania M Ortiga-Carvalho; Alice Dutra Violante; Mario Vaisman Journal: Front Endocrinol (Lausanne) Date: 2015-08-17 Impact factor: 5.555